Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress ( Patients treated with Satraplatin Demon...)

Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

Patients treated with Satraplatin Demonstrated Statistically Significant Improvement in Pain Response and PSA Response Rates

BERLIN, March 22, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation and GPC Biotech AG today announced additional data from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer) which were presented today at the 22nd Annual European Association of Urology Congress in Berlin, Germany. The trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC) who have failed prior chemotherapy.

"Second-line chemotherapy for patients with hormone-refractory prostate cancer represents a true unmet medical need and the encouraging satraplatin data suggest that for the first time, we may have a treatment option for these patients with advanced disease," said Professor Fred Witjes, Professor of Urology, Academisch Ziekenhuis, Nijmegen, The Netherlands. "In particular, the very impressive pain and PSA response rates seen in the SPARC study, especially considering the fact that all these patients were progressive after hormones and chemotherapy, further suggest satraplatin's active anti-tumor effect in this patient population."

Data presented today from the SPARC study showed that pain response rates for patients treated with satraplatin were statistically significantly superior compared to the pain response rates for those patients in the comparator arm. Pain response rates were 24.2 percent for the satraplatin plus prednisone arm compared with 13.8 percent for the placebo arm (p=0.005).

Pain response was assessed by patients using a weekly present pain intensity (PPI) and analgesic score. The PPI score was defined according to the McGill-Melzack questionnaire with 0 = no pain, 1 = mild pain, 2 = discomforting pain, 3
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association

Post Your Comments:

( Patients treated with Satraplatin Demon...)Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress,Health